MW
Therapeutic Areas
BioArctic AB Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Lecanemab (Leqembi®) | Early Alzheimer's Disease | Approved |
| BAN2802 | Alzheimer's Disease | Preclinical |
| Lecanemab SC | Alzheimer's Disease | Phase 3 |
| ABBV-0805 | Parkinson's Disease | Phase 1 |
| BAN1202 | Parkinson's Disease | Preclinical |
Leadership Team at BioArctic AB
GO
Gunilla Osswald
Chief Executive Officer
JI
Johan Ihre
Chief Financial Officer
EO
Erika Otterström-Lindblad
Chief Operating Officer
PG
Pär Gellerfors
Chief Scientific Officer
EW
Elin Winblad
Chief Medical Officer
EN
Eva Nise
Chief Human Resources Officer
ML
Mikael Lindstam
Chief Business Development Officer
CH
Christopher H. van der Kaay
Vice President, Investor Relations & Corporate Communications
MP
Mats Pettersson
Board Member
SL
Susanne Ljung
Board Member